Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Tahiri, Andliena ^a,b   Røe, Kathrine ^a   Ree, Anne H ^a,b   de Wijn, Rik ^c   Risberg, Karianne ^a   Busch, Christian ^d   Lønning, Per E ^d,e   Kristensen, Vessela ^a,b   Geisler, Jürgen ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c PamGene International BV   (Netherlands)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; SUNITINIB; VEMURAFENIB;

ADULT; AGED; ARTICLE; BRAF GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EX VIVO STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; METASTATIC MELANOMA; PROTEIN PHOSPHORYLATION; SKIN; STRAIN DIFFERENCE; WILD TYPE;

AGED; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTANT PROTEINS; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 84883358777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072692     Document Type: Article

References (40)

1. Serrone L, Zeuli M, Sega FM, Cognetti F, (2000) Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19: 21-34.
2. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
3. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365.
4. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
5. Villanueva J, Vultur A, Herlyn M, (2011) Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 71: 7137-7140.
6. Alcala AM, Flaherty KT, (2012) BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 18: 33-39.
7. Sharma SV, Settleman J, (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231.
8. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, et al. (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379: 633-640.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology 13: 239-246.
10. Joensuu G, Joensuu T, Nupponen N, Ruutu M, Collan J, et al. (2012) A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy. Acta Oncologica 51: 130-133.
11. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, et al. (2010) Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 16: 3356-3367.
12. Busch C, Geisler J, Knappskog S, Lillehaug JR, Lonning PE, (2010) Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine. J Invest Dermatol 130: 2514-2516.
13. Busch C, Geisler J, Lillehaug JR, Lonning PE, (2010) MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 46: 2127-2133.
14. Westerhuis JA, Hoefsloot HCJ, Smit S, Vis DJ, Smilde AK, et al. (2008) Assessment of PLSDA cross validation. Metabolomics 4: 81-89.
15. Kanehisa M, Goto S, (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research 28: 27-30.
16. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M, (2012) KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Research 40: 109-114.
17. Lai F, Jiang CC, Farrelly ML, Zhang XD, Hersey P, (2012) Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Res 22: 244-251.
18. Lai F, Jin L, Gallagher S, Mijatov B, Zhang XD, et al. (2012) Histone deacetylases (HDACs) as mediators of resistance to apoptosis in melanoma and as targets for combination therapy with selective BRAF inhibitors. Adv Pharmacol 65: 27-43.
19. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine 367: 1694-1703.
20. Jeter JM, Cranmer LD, Hersh EM, (2012) Ipilimumab pharmacotherapy in patients with metastatic melanoma. Clinical Medicine Insights Oncology 6: 275-286.
21. Barouch-Bentov R, Sauer K, (2011) Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs 20: 153-208.
22. Folkvord S, Flatmark K, Dueland S, de Wijn R, Groholt KK, et al. (2010) Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. Int J Radiat Oncol Biol Phys 78: 555-562.
23. Versele M, Talloen W, Rockx C, Geerts T, Janssen B, et al. (2009) Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout. Molecular Cancer Therapeutics 8: 1846-1855.
24. Sikkema AH, Diks SH, den Dunnen WFA, ter Elst A, Scherpen FJG, et al. (2009) Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery. Cancer Res 69: 5987-5995.
25. Lindholm EM, Kristian A, Nalwoga H, Kruger K, Nygard S, et al. (2012) Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. Mol Oncol 6: 418-427.
26. Tsai KY, Vin H, Leung M, Chitsazzadeh V, Ojeda S, et al. (2012) Suppression of apoptosis by BRAF inhibitors through off-target inhibition of JNK signaling. 2012 ASCO Annual Meeting. Chicago, Illinois.
27. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, et al. (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 107: 14903-14908.
28. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, et al. (2010) PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23: 190-200.
29. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
30. Weber CK, Slupsky JR, Kalmes HA, Rapp UR, (2001) Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61: 3595-3598.
31. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, et al. (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66: 9483-9491.
32. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, et al. (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364.
33. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, et al. (2012) BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer discovery 2: 791-797.
34. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, et al. (2010) Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12: 637-649.
35. Sondergaard JN, Nazarian R, Wang Q, Guo DL, Hsueh T, et al. (2010) Differential sensitivity of melanoma cell lines with BRAF(V600E) mutation to the specific Raf inhibitor PLX4032. Journal of Translational Medicine 8.
36. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390.
37. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71: 2750-2760.
38. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
39. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103.
40. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.